DE69705936D1 - Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose - Google Patents

Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose

Info

Publication number
DE69705936D1
DE69705936D1 DE69705936T DE69705936T DE69705936D1 DE 69705936 D1 DE69705936 D1 DE 69705936D1 DE 69705936 T DE69705936 T DE 69705936T DE 69705936 T DE69705936 T DE 69705936T DE 69705936 D1 DE69705936 D1 DE 69705936D1
Authority
DE
Germany
Prior art keywords
vhl
gene
lindau
disease
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69705936T
Other languages
English (en)
Inventor
W Linehan
I Lerman
Farida Latif
Berton Zbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69705936D1 publication Critical patent/DE69705936D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DE69705936T 1996-03-28 1997-03-27 Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose Expired - Lifetime DE69705936D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/623,428 US6312890B1 (en) 1993-05-14 1996-03-28 Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease
PCT/US1997/005059 WO1997035978A1 (en) 1996-03-28 1997-03-27 Partial intron sequence of von hippel-lindau (vhl) disease gene and its use in diagnosis of disease

Publications (1)

Publication Number Publication Date
DE69705936D1 true DE69705936D1 (de) 2001-09-06

Family

ID=24498052

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69705936T Expired - Lifetime DE69705936D1 (de) 1996-03-28 1997-03-27 Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose

Country Status (8)

Country Link
US (1) US6312890B1 (de)
EP (1) EP0889959B1 (de)
JP (1) JP2000507823A (de)
AT (1) ATE203766T1 (de)
AU (1) AU2593197A (de)
CA (1) CA2250452A1 (de)
DE (1) DE69705936D1 (de)
WO (1) WO1997035978A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
CA2418094A1 (en) * 2000-08-09 2002-02-14 Dzgenes Llc Vhl promoter diagnostic polymorphism
US20040166491A1 (en) * 2001-08-09 2004-08-26 Henderson Lee A Vhl promoter diagnostic polymorphism
US20050208023A1 (en) * 2002-07-19 2005-09-22 Krissansen Geoffrey W Tumor treating composition and methods
US20060134708A1 (en) * 2004-10-14 2006-06-22 Northwestern University Detection and treatment of renal cancer
US7549447B1 (en) * 2007-12-01 2009-06-23 Joe Garbo Pressure valve inlet cover system
KR101064603B1 (ko) 2008-11-13 2011-09-15 한국생명공학연구원 리포터 시스템을 이용한 메틸트렌스퍼레이즈 저해 물질 스크리닝 방법
AU2012339835B2 (en) 2011-11-17 2016-01-28 The Johns Hopkins University Differential identification of pancreatic cysts
EP2957571B1 (de) * 2014-06-17 2018-08-15 Centre National De La Recherche Scientifique (Cnrs) Monoklonale anti-pvhl-antikörper und anwendungen davon
CN105112532A (zh) * 2015-09-15 2015-12-02 北京大学第一医院 一种检测vhl基因大片段缺失的杂交探针及检测方法与试剂盒
CN105063231A (zh) * 2015-09-15 2015-11-18 北京大学第一医院 一种羊水中胎儿细胞vhl基因突变检测方法及试剂盒
CN105087808A (zh) * 2015-09-15 2015-11-25 北京大学第一医院 一种检测vhl基因突变的方法及试剂盒
CN105087809A (zh) * 2015-09-15 2015-11-25 北京大学第一医院 一种快速检测羊水中胎儿细胞vhl基因突变的方法及试剂盒
CN113913529A (zh) * 2021-12-01 2022-01-11 济南艾迪康医学检验中心有限公司 检测VHL基因c.-195G>A位点突变的方法、引物和试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654138A (en) * 1993-05-14 1997-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Von hippel-lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene

Also Published As

Publication number Publication date
ATE203766T1 (de) 2001-08-15
EP0889959A1 (de) 1999-01-13
CA2250452A1 (en) 1997-10-02
EP0889959B1 (de) 2001-08-01
JP2000507823A (ja) 2000-06-27
US6312890B1 (en) 2001-11-06
WO1997035978A1 (en) 1997-10-02
AU2593197A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
ATE256186T1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
ATE247717T1 (de) Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE275417T1 (de) Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
ES2135581T3 (es) Gen de la enfermedad de von hippel-lindau (vhl) y cdna correspondiente y metodos para detectar portadores del gen de la enfermedad de vhl.
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE256753T1 (de) Genetischer test zur bestimmung der nicht- wirksamkeit einer behandlung mit statinmedikamenten
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
Oota et al. Genetic study of the Paleolithic and Neolithic Southeast Asians
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
DE69827805D1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
DE3688528T2 (de) Optische analoge datenverarbeitungsanordnungen zur behandlung von bipolaren und komplexen daten.
PT1009768E (pt) Persefina e factores de crescimento relacionados
GB9610281D0 (en) Diagnostic method and apparatus
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Legal Events

Date Code Title Description
8332 No legal effect for de